S. 1954Introduced
Biosimilar Red Tape Elimination Act
Plain-English overview
What this bill does
Deems FDA-licensed biosimilars interchangeable with their reference biological products by removing extra interchangeability requirements and preserving certain existing exclusivity periods
Key points
- Abolish interchangeability requirements
- Declare licensed biosimilars interchangeable
- Preserve existing exclusivity periods
Current status
Where it stands
Status
Introduced
Latest action
2026-07-27 — Placed on Senate Legislative Calendar under General Orders. Calendar No. 521.
Related context
Topics and policy areas
Select a topic to continue exploring related legislation, members, and committees.
Discovery signals
About these signals
Impact and Momentum are relative discovery aids calculated by Legislation Lemur. They help you scan the congressional record; they are not predictions, endorsements, ideological ratings, or measures of policy importance.
Impact ScoreOverall observed legislative footprint and accumulated activity.
MomentumHow recently active or changing the bill appears in available data.